Navigation Links
Ranbaxy and Pfizer Settle Lipitor Litigation Worldwide

Ranbaxy Will Market Generic Atorvastatin in the U.S. With 180 Days

Exclusivity From Nov. 30, 2011

Agreement Also Resolves Caduet, Accupril Litigation in the US

GURGAON, Harayana, India and PRINCETON, N.J., June 18 /PRNewswire/ -- Ranbaxy Laboratories Limited (Ranbaxy), announced today that it has entered into an agreement with Pfizer Inc. to settle most of the patent litigation worldwide involving Atorvastatin (Lipitor), the world's most-prescribed cholesterol-lowering medicine. This decision will allow for an earlier introduction of a generic formulation that will benefit patients and many healthcare systems throughout the world. Lipitor is the world's largest selling drug with worldwide sales in 2007 of $12.7 billion.

The agreement pertains solely to Ranbaxy and its affiliates and does not cover legal challenges to the Lipitor patents involving other generic manufacturers. However, as Ranbaxy was the first generic challenger to the listed Lipitor patents, it retains the right to the marketing exclusivity of 180 days in the United States. Under the terms of the agreement, Ranbaxy will have a license to sell generic versions of Atorvastatin and the fixed-dose combination of Atorvastatin-Amlodipine besylate in the United States effective Nov. 30, 2011.

Welcoming the development, Malvinder Mohan Singh, CEO and MD, Ranbaxy Laboratories Ltd., said, "This comprehensively settles outstanding issues between Ranbaxy and Pfizer bringing to closure a number of ongoing patent disputes. It also provides certainty and visibility to the launch of Ranbaxy's Generic Atorvastatin, with 180-day market exclusivity in the US and an early entry in other markets. This will make the worlds largest selling drug more accessible to patients who will gain from the timely availability of an affordable quality option."

Ranbaxy will also have a license to sell Atorvastatin on varying dates in an additional 7 countries, including: Canada, Belgium, Netherlands, Germany, Sweden, Italy and Australia. Ranbaxy and Pfizer have also resolved their disputes regarding Atorvastatin in Malaysia, Brunei, Peru and Vietnam.

In addition, the lawsuits between Pfizer and Ranbaxy regarding Atorvastatin will be dismissed in select countries and the lawsuits between Pfizer and Ranbaxy regarding the fixed dose combination product containing Atorvastatin and amlodipine will be dismissed in the U.S. and Ranbaxy will no longer contest the validity of Pfizer's patents in such countries. Such patent challenges by Ranbaxy regarding Lipitor have been underway in numerous markets since 2003.

The Atorvastatin patents involved in this agreement are the basic compound patent, which expires in the United States in 2010; the enantiomer patent, which expires in the United States in 2011; and various process and crystalline form patents, which expire in 2016 and 2017; and the combination patent for fixed-dose combination product which expires in 2018.

The agreement also covers the fixed-dose combination of Atorvastatin-Amlodipine besylate (presently marketed under the brand Caduet, which also contains crystalline Form I Atorvastatin), a fixed-dose combination product indicated for patients suffering from both high blood pressure and high levels of cholesterol. The patent for the fixed-dose combination expires in 2018. The settlement also resolves additional patent litigation between the companies involving the branded drugs Accupril (in the U.S.) and Viagra (in Ecuador) and all patent litigation with Ranbaxy relating to generic formulation of Quinapril hydrochloride in the United States and Sildenafil in Ecuador.

Litigation between Ranbaxy and Pfizer relating to Lipitor will continue in five other European countries -- Finland, Spain, Portugal, Denmark and Romania.

About Ranbaxy Laboratories Limited

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies," resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 11 countries.

For further information please contact:

Ramesh L. Adige

Executive Director - Corporate Affairs and Global Corporate Communications

Ranbaxy Laboratories Ltd.

Plot 90, Sector 32, Gurgaon

Haryana122001, India

Tel: +91-124-4135000



Raghu Kochar

Director - Corporate Communications

Ranbaxy Laboratories Ltd.

Plot 90, Sector 32, Gurgaon

Haryana122001, India

Tel: +91-124-4135141

Mobile: 9811617256



Krishnan Ramalingam

Sr. Manager - Corporate Communications

Plot 90, Sector 32, Gurgaon

Haryana122001, India

Tel: +91-124-4135143

Mobile: 9810042540

e-mail: krishnan.ramalingam@ranbaxy


Chuck Caprariello

Vice President, Corporate Communications and Government Affairs

Ranbaxy Inc.

600 College Road East

Princeton, NJ 08540

Tel: 609-720-5615

Mobile: 609-462-7354


SOURCE Ranbaxy Laboratories Limited
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Ranbaxy to Bring in Daiichi Sankyo as Majority Partner; Strategic Combination Creates Innovator and Generic Pharma Powerhouse
2. Ranbaxy Receives Final Approval to Manufacture and Market Cetirizine Hydrochloride Oral Solution
3. Ranbaxy Gains Approval to Manufacture and Market Cefuroxime Axetil for Oral Suspension
4. Ranbaxy Receives Final Approval to Manufacture and Market Cetirizine Hydrochloride Tablets (OTC), 5mg and 10mg
5. Ranbaxy Receives Tentative Approval For Valsartan Tablets
6. Ranbaxy First to Gain Approval to Manufacture and Market Clarithromycin for Oral Suspension, USP
7. Ranbaxy Gains Approval to Manufacture and Market Carvedilol Tablets in the U.S. Market
8. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
9. Novartis, Pfizer and Merck Take the Lead on Strong Relationships with Physicians, as Doctors Demand an Expanding Set of Services
10. Pfizers work on penicillin for World War II becomes a National Historic Chemical Landmark
11. AUDIO from Medialink and Pfizer: Free Programs for Uninsured Men and Women Who Need Help Paying for Medicine
Post Your Comments:
(Date:10/12/2015)... ... 2015 , ... FEI Behavioral Health, a social enterprise with ... management, will present a session at the Wisconsin Society for Human Resource Management ... Chief Operating Officer Daniel Potterton will present an informative workshop, “Training HR to ...
(Date:10/12/2015)... ... October 12, 2015 , ... ... part of a contact channel benchmarking study. Be a part of ... operational strategies for improving customer experience, customer journey, contact channel execution and intelligence, ...
(Date:10/12/2015)... DC (PRWEB) , ... October 12, 2015 , ... ... been selected to receive a Eugene Washington Engagement Award by the Patient-Centered Outcomes ... more effectively with the research community. , The project, entitled “Training Patients ...
(Date:10/12/2015)... ... 12, 2015 , ... The translation for ARIS® 7.x and 9.x to Microsoft ... installations into the Microsoft world. The ARIS models will be fully translated and mapped ... for both IT and Office users it is acknowledged as a competitive alternative to ...
(Date:10/12/2015)... ... October 12, 2015 , ... METTLER TOLEDO is ... processes. In addition, METTLER TOLEDO has collaborated with manufacturing consultant and lean laboratory ... help improve productivity through the identification and elimination of 'hidden' time-wasting activities. Mr ...
Breaking Medicine News(10 mins):
(Date:10/12/2015)... This study focuses on China,s Genome-Based ... decades, the industry has been growing at a fast pace. ... consumptions in China have transformed ... is one of the world,s major producers for ... world, China is the world,s fastest ...
(Date:10/12/2015)... -- About epilepsy --> ... disorders manifested by benign to severe, disabling, and life-threatening ... malformations and tumors to meningitis, high-risk pregnancies, and trauma ... is unidentified, as is witnessed in the majority of ... between the inhibitory and excitatory signals of the brain, ...
(Date:10/12/2015)... Oct. 12, 2015 A new computer program ... can predict whether they will develop effective language skills ... a study in the journal Brain and Behavior ... In the journal,s Oct. 12 online edition, researchers ... program determines how specific regions of the brain respond ...
Breaking Medicine Technology: